Top of page Skip navigation
  • CHECK-OUT OUR SUPPORTER PACKAGES

    Only a few options remain for this leading conference

Programme

Tuesday 28 November

19.00 - 21.00

Join us at Cardiff Castle for an informal evening of networking ahead of the conference.  Ideal for those arriving early in Cardiff. The evening is kindly supported by Merck.

Places are limited.

Wednesday 29 November

09.15 - 10.00

Refreshments, networking, exhibition and partnering

10.00 - 10.10

Welcome

Dr Nigel Darby
Executive Advisor, GE Healthcare Life Sciences

10.10 - 10.20

BIA update

Steve Bates OBE
Chief Executive Officer, BIA

10.20 - 11.30

Post Industrial Strategy - growing UK biotech

Chair
Steve Bates OBE
Chief Executive Officer, BIA

Speakers/Panel
John Hodgson
Executive Editor,, Informa

Ian McCubbin
Advanced Therapies Manufacturing Task Force 

Jo Pisani
Partner, Strategy&, PwC

Dr Mike Sullivan
Head of Advanced Therapies, Innovate UK

11.30 - 12.00

 Refreshment, networking, exhibition, poster display and partnering

12.00 - 12.15

Richard Wilson Impact Award

Presented by

Dr Stephen Ward
Chief Operating Officer, Cell and Gene Therapy Catapult, and Chair of BIA Manufacturing Advisory Committee

12.15 - 13.15

Young Researchers poster flash presentations

In this fast-moving session kindly supported by Pall Life Sciences, we hear from 20 early career researchers as they give a snapshot of their work and poster which is on display in the main exhibition area.

Chair
Dr Peter Levison
Senior Marketing Director - Downstream Processing, Pall Life Sciences 

13.15 - 14.30

Lunch, networking, exhibition, poster display and partnering

14.30 - 16.00

Workshops

14.30 - 16.00

Purification of next generation medicines

The bioindustry is at a nexus between traditional recombinant protein production and supporting next generation biologic based medicines.  Do the manufacturing paradigms and technologies, developed in the 20th century for IgGs, still hold true for innovative therapies in the 21st?

This workshop will focus on some new areas of bioprocess research from the latest chromatography resins to insights of novel molecule production.     

Chair
Dr Richard Turner
Head of Downstream Processing,MedImmune

Primary capture purification offering new single-use bioprocessing opportunities

Purification productivities of 100’s g/L/h can be achieved by utilising the high flowrate and high capacities of nanofibres. This means for an equivalent bioreactor harvest, a significantly smaller nanofibre adsorbent cartridge can be used if rapid cycling is employed. The use of smaller, pre-packed, plug and play units, for preparative protein capture improves process flexibility in an effort to maximise facility productivity.

Dr Oliver Hardick
Chief Executive Officer, Puridify

 

Title TBC
Dr John Liddell
NBMC

Title TBC
Dr Dan Smith
Chief Scientific Officer, Cobra Biologics

 

Development of the next generation protein A chromatography resin

Protein A based affinity chromatography is well-established as the capture step in monoclonal antibody purification processes due to the high degree of selectivity and purity obtained. Increasing titres and a demand for better cleaning in place and sanitization procedures calls for protein A chromatography resins with improved features such as higher dynamic binding capacity and better alkaline stability. This presentation will highlight the development and evaluation of a novel protein A chromatography resin. Binding capacity data, alkaline stability and resin performance, in terms of yield and purity, will also be presented.

Dr Kajsa Stridsberg-Friden
R&D Senior Project Manager, GE Healthcare Life Sciences

Adaptive manufacturing

Chair
Professor Alan Dickson
University of Manchester

Speakers

DOE, machine learning and automation: Demonstrating Antha, a powerful platform for biology

Deceptively simple from the lab user's perspective, the Antha software platform integrates and controls lab devices and automation (across models and manufacturers), enabling highly complex experimentation to be carried out with ease. Its applications span research and development, bioprocess development and optimisation as well as analytics and quality management. See a demonstration of the Antha software and discuss how it can be applied in adaptive manufacturing.

Dr Markus Gershater
Chief Scientific Officer, Synthace

Title TBC
Dr Damian Marshall
Head of Analytical Development, Cell and Gene Therapy Catapult

Title TBC
Dr Andy Topping
Chief Scientific Officer, FUJIFILM Diosynth Biotechnologies

Adaptive process control for next generation biologics and biomanufacturing of the future

Biologics are becoming increasingly complex in terms of therapeutic properties and the conditions required to manufacture them. The diversifying pipelines within the biologics industry present a significant challenge during process development and through into biomanufacturing.  A game changing solution to such challenges is the adoption of adaptive process control techniques. A review of the state-of-the-art, including a  number of case studies, will be presented giving insight into the use of adaptive process control during upstream process development and manufacturing

Dr Sam Watts
Technical Business Development Officer, Stratophase

Medicines Manufacturing Industry Partnership (MMIP)
Leaders in key UK manufacturing sites will discuss the attractiveness of the UK for investment in medicines manufacturing, utilising what we do well but also identifying what we need to work on, through MMIP, to ensure continued growth of the sector.

Chair
Andy Evans
Head of Macclesfield Site, AstraZeneca

Speakers/Panel
Steve Bagshaw
Chief Executive Officer, FUJIFILM Diosynth Biotechnologies

Dr Crawford Brown
Senior Vice President Biologics R&D, Allergan

Dr Jim Faulkner
Head of Manufacturing, Autolus

16.00 - 16.30

Refreshments, networking, exhibition and partnering

16.30 - 17.00

Outputs from workshops

In this session, we will hear from workshop chairs on the feedback as they present back to conference attendees

17.00 - 17.45

Peter Dunnill Award Presentation and Lecture

 

17.45 - 17.50

Summary and close of day one

19.00 - 23.00

Drinks reception and conference dinner

Conference attendees, exhibitors and supporters are invited to join us at the National Museum of Cardiff  for an informal networking drinks reception while enjoying the galleries, followed by evening dinner in the Grand Hall

08.45 - 14.30

Thursday 30 November

08.45 - 09.15

Refreshments, networking, exhibition, poster display and partnering

09.15 - 10.45

Application of platform technologies in developing vaccines for emerging diseases, biological threats and unmet needs

Chair
Dr Steve Chatfield
Chairman, Prokarium

Speakers
The Spy Toolbox for Plug-and-Display Vaccination
We have generated protein superglues from bacteria to accelerate the production of vaccines. Using Plug-and-Display technology, antigens from viruses, bacteria or self-proteins are irreversibly linked on to virus-like particles. This modular production generates potent antibody responses and can enhance the preparation against emerging pandemics.

Professor Mark Haworth
Co-Founder, SpyBiotech

Title TBC
Dr Tarit Mukhopadhyay
Senior Lecturer, University College London

Oral  Vaccination - a Pharmaceutical Approach

An encapsulation technology which brings together antigens, immunostimulants, oils and polysaccharides all in the same vehicle is an ideal candidate for an oral vaccine.  Proof of principle and demonstration of efficacy will be shown here for important diseases such as avian 'flu, infantile diarrhoea and plague

Dr Roger New
Proxima Concepts 

 

10.45 - 11.15

Refreshments, networking, exhibition, poster display and partnering

11.15 - 13.15

Delivering Cell and Gene therapies to patients

Chair
Dr Stephen Ward
Chief Operating Officer, Cell and Gene Therapy Catapult and Chair of BIA Manufacturing Advisory Committee

Speakers
Cellular Therapeutics - a decade of experience in T cell multi-product manufacturing in oncology

T cell therapy of cancer has moved from a scientific theory to a medicine, recommended for marketing approval, for patient treatment within two decades. In order for these treatments to become widely available manufacturing needs to move from the small scale, highly complex processes, to industrialised, high throughput. This will also require specialised training for clinicians to allow hospital roll-out. An exciting time ahead challenging the infrastructure, legislation and a new era in the patient/pharma relationship.

Dr Ryan Guest
Director of Cell Production and Co-founder,Cellular Therapeutics

Delivery of Adoptive Immunotherapy Medicines to Patients- Building and Establishing an Effective Supply Chain
A number of adoptive immunotherapies are now preparing for market approval but challenges still exist to ensure patient access to these ground-breaking medicines. Innovative solutions and approaches are required across manufacturing, supply chain and the regulatory framework

Dr Bo Kara
Head Process Development, Cell and Gene Therapy Platform CMC, GlaxoSmithKline

Title - TBC
Professor Amit Nathwani
Professor of Haematology, UCL

Manufacturing cell and gene therapies:  challenges and opportunities for this new class of therapies

Advanced therapies bring clinical practice and pharmaceutical development closer than ever. Cell and gene therapies introduce significant complexity into manufacturing and supply chains including custody management and cold-chain distribution. Automation and new manufacturing paradigms will be needed to match supply to demand and to help assure a supply of these treatments in the future

Dr Phil Vanek
General Manager, Cell Therapy Technologies, GE Healthcare Life Sciences

13.15 - 13.20

Announcement of Early Career Researchers Poster Prize Competition Winner

13.20 - 13.30

Closing remarks

Steve Bates OBE
Chief Executive Officer, BIA

13.30 - 14.30

Lunch, networking, exhibition and partnering